Source-grounded facts extracted from HAEMONETICS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HAEMONETICS CORP reported financial results for the fourth quarter and fiscal year ended March 28, 2026.
“On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026.”
Charles J. Dockendorff departed as Director at HAEMONETICS CORP.
“On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).”
Frank W. Chan was appointed as Executive Vice President, Chief Operating Officer at HAEMONETICS CORP.
“On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.”
Josep Llorens retired as Executive Vice President, Global Manufacturing and Supply Chain at HAEMONETICS CORP.
“Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.”
Anila Lingamneni departed as Executive Vice President, Chief Technology Officer at HAEMONETICS CORP.
“Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.”
HAEMONETICS CORP reported financial results for the fourth quarter and fiscal year ended March 30, 2024.
“Item 2.02 Results of Operations and Financial Condition. On May 9, 2024 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 30, 2024.”
HAEMONETICS CORP incurred revolving credit of $750 million senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
“The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.”
HAEMONETICS CORP incurred credit facility of $250 million senior unsecured term loan with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
“The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.”
HAEMONETICS CORP amended Revised Credit Agreement with JPMorgan Chase Bank, N.A. valued at $250 million senior unsecured term loan (effective 2024-04-30).
“On April 30, 2024, Haemonetics Corporation (the “Company”) entered into a second amended and restated credit agreement by and among the Company, as borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Revised Credit Agreement”).”
HAEMONETICS CORP reported financial results for third quarter and nine months ended December 30, 2023.
“On February 8, 2024, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 30, 2023.”
HAEMONETICS CORP reported financial results for the second quarter ended September 30, 2023.
“On November 2, 2023, Haemonetics Corporation issued a press release announcing financial results for the second quarter ended September 30, 2023 and first half of fiscal 2024.”
HAEMONETICS CORP entered into Arrangement Agreement with OpSens Inc., 9500-7704 Québec Inc. valued at CAD $2.90 (effective 2023-10-10).
“On October 10, 2023, Haemonetics Corporation, a Massachusetts corporation (“ Haemonetics ” or the “ Company ”), OpSens Inc., a corporation existing under the Business Corporations Act (Québec) (“ OpSens ”), and 9500-7704 Québec Inc., a corporation existing under the Business Corporations Act (Québec) and a wholly owned subsidiary of Haemonetics (the “ Purchaser ” and, together with Haemonetics, the “ Purchaser Parties ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”), pursuant to which, among other things, the Purchaser has agreed to acquire all of the issued and outstanding common shares of OpSens (the “ Arrangement ”).”
HAEMONETICS CORP reported financial results for the first quarter ended July 1, 2023.
“On August 8, 2023, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended July 1, 2023.”
Diane M. Bryant was elected as Director at HAEMONETICS CORP.
“On August 4, 2023, the Board of Directors of Haemonetics Corporation (the “Company”) elected Diane M. Bryant as a director of the Company, effective immediately.”
HAEMONETICS CORP reported financial results for the fourth quarter and fiscal year ended April 1, 2023.
“On May 11, 2023 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended April 1, 2023.”
HAEMONETICS CORP reported financial results for third quarter and nine months ended December 31, 2022.
“On February 7, 2023, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 31, 2022.”
Maryanne Farris was appointed as Vice President, Chief Accounting Officer at HAEMONETICS CORP.
“Ms. Farris, age 47, joined the Company as Vice President, Chief Accounting Officer on October 17, 2022.”
James C. D'Arecca was appointed as principal accounting officer at HAEMONETICS CORP.
“On August 5, 2022, the Board of Directors of Haemonetics Corporation (the “Company”) appointed James C. D’Arecca, Executive Vice President, Chief Financial Officer, as the Company’s principal accounting officer”
Michelle L. Basil changed role as Executive Vice President, General Counsel at HAEMONETICS CORP.
“On June 16, 2022, Haemonetics Corporation (the “Company”) announced that Michelle L. Basil, Executive Vice President, General Counsel has decided to transition from the Company effective October 31, 2022.”
Dan Goldstein departed as Vice President, Corporate Controller and Principal Accounting Officer at HAEMONETICS CORP.
“Dan Goldstein, Vice President, Corporate Controller and Principal Accounting Officer will leave Haemonetics Corporation (the “Company”) on August 9, 2022.”
James C. D'Arecca was appointed as Chief Financial Officer at HAEMONETICS CORP.
“On March 21, 2022, the Company announced the appointment of James C. D’Arecca as its Chief Financial Officer, effective April 11, 2022.”
William P. Burke retired as Chief Financial Officer at HAEMONETICS CORP.
“Mr. Burke will step down as Chief Financial Officer and principal financial officer of the Company on April 11, 2022”
William P. Burke departed as Executive Vice President, Chief Financial Officer at HAEMONETICS CORP.
“William P. Burke, Executive Vice President, Chief Financial Officer (“CFO”) has decided to retire from the Company in June 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.